报价延迟最少15分钟:2026/04/13 12:04 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.57 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.69/-0.75
|
|
企业价值
108.12M
|
| 资产负债 |
|
每股账面净值
0.66
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
593.00K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targetingtumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States. |
